Abstract:Background: Acute lung injury caused by renal ischemia-reperfusion is one of the leading causes of acute kidney injury-related death. Dexmedetomidine, an alpha(2)-adrenergic agonist sedative, has been found to have protective effects against acute kidney injury and remote lung injury. We sought to determine whether dexmedetomidine can exert its anti-apoptotic effects in acute lung injury after acute kidney injury, in addition to its common anti-inflammatory effects, and to determine the underlying mechanisms.Methods: In vivo, acute kidney injury was induced by 60 min of kidney ischemia (bilateral occlusion of renal pedicles) followed by 24 h of reperfusion. Mice received dexmedetomidine (25 mu g/kg, i.p.) in the absence or presence of alpha(2)-adrenergic antagonist atipamezole (250 mu g/kg, i.p.) before IR. Histological assessment of the lung was conducted by HE staining and arterial blood gases were measured. Lung apoptosis was assessed by terminal deoxynucleotidyl transferase-mediated dUTP nick end-labeling assay. The expression of caspase 3 and p-Akt in lung tissue was detected by western blot. In vitro, C57BL/6J mice pulmonary microvascular endothelial cells were treated with serum from mice obtained following sham or IR. Dexmedetomidine was given before serum stimulation in cells, alone or with atipamezole or LY294002. Cell viability was assessed by CCK 8 assay. Cell apoptosis was examined by Hoechst staining and Annexin V-FITC/PI staining flow cytometry analysis. Mitochondrial membrane potential was measured by flow cytometry. The expression of p-Akt, caspase 3, Bcl-2 and Bax was measured by western blot.Results: In vivo, dexmedetomidine remarkably mitigated pathohistological changes and apoptosis and significantly increased p-Akt expression in the lung. In addition, dexmedetomidine also slightly improved oxygenation in mice after IR, which can be abolished by atipamezole. In vitro, dexmedetomidine significantly inhibited IR serum-induced loss of viability and apoptosis in PMVECs. Dexmedetomidine increased p-Akt in a time-and dose-dependent manner, and down-regulated the expression of caspase 3 and Bax and up-regulated the Bcl-2 expression in PMVECs. The changes of MMP were also improved by dexmedetomidine. Whilst these effects were abolished by Atipamezole or LY294002.Conclusion: Our results demonstrated that dexmedetomidine attenuates lung apoptosis induced by IR, at least in part, via alpha(2)AR/PI3K/Akt pathway.

Dexmedetomidine pretreatment attenuates myocardial ischemia reperfusion induced acute kidney injury and endoplasmic reticulum stress in human and rat

Both PI3K/Akt and ERK1/2 Pathways Participate in the Protection by Dexmedetomidine Against Transient Focal Cerebral Ischemia/reperfusion Injury in Rats

Dexmedetomidine Attenuates Ischemia/Reperfusion-Induced Myocardial Inflammation and Apoptosis Through Inhibiting Endoplasmic Reticulum Stress Signaling

Dexmedetomidine Attenuates Renal and Myocardial Ischemia/Reperfusion Injury in a Dose-Dependent Manner by Inhibiting Inflammatory Response.

Dexmedetomidine provides renoprotection against ischemia-reperfusion injury in mice

Dexmedetomidine Pretreatment Reduces Myocardial Ischemia And Reperfusion Injury In Rats By Altering Jak/Stat And Pi3k/Akt Levels

Dexmedetomidine Preconditioning Inhibits the Long Term Inflammation Induced by Renal Ischemia/reperfusion Injury in Rats.

Effects of dexmedetomidine on renal microcirculation in ischemia/reperfusion-induced acute kidney injury in rats

Effects Of Dexmedetomidine Pretreatment On Tnf-Alpha And Il-6, Oxidative Stress And Myocardial Apoptosis Of Rats After Myocardial Ischemia-Reperfusion Injury

Effect of Dexmedetomidine on Kidney Injury Induced by Liver Ischemia-Reperfusion in Rats

Dexmedetomidine Alleviates Myocardial Injury Induced by Acute Kidney Injury in Diabetes Mellitus Rats via Regulating the Inflammatory Response

Protective effects of dexmedetomidine preconditioning in rats with myocardial ischemia reperfusion injury and the effects on calcium regulatory proteins

Dexmedetomidine protects against renal ischemia and reperfusion injury by inhibiting the P38-MAPK/TXNIP signaling activation in streptozotocin induced diabetic rats.

Protective Effect of Dexmedetomidine on Inflammation Induced by Renal Ischemia and Reperfusion Injury in Rats

Dexmedetomidine Pretreatment Protects Against Myocardial Ischemia/Reperfusion Injury by Activating STAT3 Signaling

Dexmedetomidine Ameliorates Acute Stress-Induced Kidney Injury by Attenuating Oxidative Stress and Apoptosis Through Inhibition of the ROS/JNK Signaling Pathway

Pretreatment with dexmedetomidine alleviates lung injury in a rat model of intestinal ischemia reperfusion

Dexmedetomidine Exerts Renal Protective Effect by Regulating the PGC-1α/STAT1/IRF-1 Axis

Dexmedetomidine Attenuates Lung Apoptosis Induced By Renal Ischemiareperfusion Injury Through Alpha(2)Ar/Pi3k/Akt Pathway

Effect of Dexmedetomidine Pretreatment on Lung Injury Following Intestinal Ischemia-Reperfusion

Dexmedetomidine Attenuates Myocardial Ischemia-Reperfusion Injury in Hyperlipidemic Rats by Inhibiting Inflammation, Oxidative Stress and NF-B